ClinicalTrials.gg
CompletedNCT00384059Updated Jan 24, 2013Results posted

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 7vPnC in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 11 sites in United Kingdom. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-24.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccines in the United Kingdom.

02

Conditions studied

  • Vaccines, Pneumococcal
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 2 months (42 to 98 days) at the time of enrollment.
  2. Available for entire study period and whose parent(s)/legal guardian(s) could be reached by telephone.
  3. Healthy infant, as determined by medical history, physical examination, and judgment of the investigator.
  4. Parent(s)/legal guardian(s) had to be able to complete all relevant study procedures during study participation.

Exclusion criteria

Exclusion Criteria:

  1. Previous vaccination with licensed or pneumococcal vaccine.
  2. Previous vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, or meningococcal vaccines.
  3. A previous anaphylactic reaction to any vaccine or vaccine-related component.
  4. to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, pneumococcal conjugate, or meningococcal conjugate vaccines.
  5. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
  6. Known or suspected immune deficiency or suppression.
  7. History of culture-proven invasive disease caused by S pneumoniae, Neisseria meningitidis, or Hib.
  8. Major known congenital malformation or serious chronic disorder.
  9. Significant neurological disorder or history of seizure, including febrile seizure, or significant stable or evolving disorders, such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. This did not include resolving syndromes due to birth trauma such as Erb palsy.
  10. Receipt of blood products or gamma-globulin (including immunoglobulin and monoclonal antibodies; eg, Synagis®).
  11. Participation in another investigational trial. Participation in purely observational studies was acceptable.
  12. Infant who was a direct descendant (eg, child or grandchild) of the study site personnel.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    1

    13-valent pneumococcal vaccine

    Biological: 13-valent Pneumococcal Conjugate Vaccine · Biological: Pediacel · Biological: NeisVac-C · Biological: Menitorix

  • Active comparator
    2

    7-valent pneumococcal vaccine

    Biological: 7vPnC · Biological: Pediacel · Biological: NeisVac-C · Biological: Menitorix

Interventions

  • Single 0.5 mL dose given at 2, 3, 4, and 12 months of age

  • Biological7vPnC

    Single 0.5 mL dose given at 2, 3, 4 and 12 months of age

  • BiologicalPediacel

    concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age

  • BiologicalNeisVac-C

    concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age

  • BiologicalMenitorix

    concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series.

    Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥1:8 and predefined antibody threshold levels with the corresponding 95% CI for concomitant antigens polyribosylribitol phosphate (PRP) in haemophilus influenzae type b \[Hib\](≥0.15 μg/mL or ≥ 1.0 μg/mL), pertussis toxoid \[PT\], filamentous haemagglutinin, pertactin \[FHA\], and pertactin (PRN) (≥5 Elisa Units EU/mL) and fimbrial agglutinogens \[FIM\] (≥2.2 EU/mL) are presented.

    Time frame: One month after infant series dose 2 (5 months of age)

  2. Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series

    Time frame: one month after infant series dose 2 (5 months of age)

  3. Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series

    Time frame: one month after infant series dose 2 (5 months of age)

  4. Geometric Mean Antibody Concentration of Pertusis Filamentous Haemagglutinin (FHA), Pertussis Toxoid (PT), Pertactin (PRN), and Fimbrial Agglutinogens (FIM) as Measured by ELISA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series

    Time frame: one month after infant series dose 2 (5 months of age)

  5. Percentage of Participants in the 13vPnC Group Achieving a Serotype-specific IgG Antibody Concentration ≥0.35 µg/mL Measured 1 Month After the 2-dose Infant Series, Before and After the Toddler Dose

    Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: one month after infant series dose 2 (5 months of age), before and after toddler dose (12 months of age)

  6. Geometric Mean Antibody Concentration in 13vPnC Group After the 2-dose Infant Series, Before and After the Toddler Dose.

    Antibody concentration/geometric mean concentration (GMC) as measured by ELISA for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented with corresponding 2-sided 95% CI.

    Time frame: one month after infant series dose 2 (5 months of age) and before and after toddler dose (12 months of age)

Secondary outcomes

  1. Percentage of Participants Achieving an SBA Titer ≥1:8 for Meningococcal C in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose.

    Time frame: one month after the toddler dose (13 months of age)

  2. Percentage of Participants Achieving a Predefined Antibody Level for Haemophilus Influenzae Type b in the 13vPnC Group Relative to the 7vPnC Group After the Toddler Dose.

    Time frame: one month after toddler dose (13 months of age)

  3. Geometric Mean Antibody Concentration for Haemophilus Influenzae Type b PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose.

    Time frame: one month after toddler dose (13 months of age)

  4. Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

    Time frame: one month after toddler dose (13 months of age)

Other outcomes

  1. Percentage of Participants Reporting Pre-Specified Local Reactions

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

  2. Percentage of Participants Reporting Pre-Specified Systemic Events

    Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds) to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary; percentage of participants with each event was evaluated.

    Time frame: During the 4-day period after each dose

07

Results

Posted Aug 15, 2012

Participant flow

Participants were recruited in the United Kingdom (UK) from October 2006 to June 2007.

Infant Series
Participant flow — Infant Series
Milestone13vPnC7vPnC
Started141145
Vaccinated dose 1139139
Vaccinated dose 2136135
Completed135132
Not completed613
Withdrew: Not consented26
Withdrew: Withdrawal by subject22
Withdrew: Adverse event12
Withdrew: Protocol violation12
Withdrew: Lost to follow-up01
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC7vPnC
Started135132
Completed131122
Not completed410
Withdrew: Protocol violation23
Withdrew: Withdrawal by subject22
Withdrew: Failed to return02
Withdrew: Adverse event01
Withdrew: Physician decision01
Withdrew: Lost to follow-up01
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC7vPnC
Started131122
Completed130120
Not completed12
Withdrew: Lost to follow-up11
Withdrew: Failed to return01

Outcome measures

PrimaryPercentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series.

Percentage of participants achieving a meningococcal C SBA serum antibody titer ≥1:8 and predefined antibody threshold levels with the corresponding 95% CI for concomitant antigens polyribosylribitol phosphate (PRP) in haemophilus influenzae type b \[Hib\](≥0.15 μg/mL or ≥ 1.0 μg/mL), pertussis toxoid \[PT\], filamentous haemagglutinin, pertactin \[FHA\], and pertactin (PRN) (≥5 Elisa Units EU/mL) and fimbrial agglutinogens \[FIM\] (≥2.2 EU/mL) are presented.

Time frame:
One month after infant series dose 2 (5 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series.
Percentage of participants13vPnC7vPnC
Meningococcal C ≥ 1:8 titer (n=120,118)99.2 (95.4 to 100.0)99.2 (95.4 to 100.0)
Hib (PRP) ≥ 0.15 μg/mL (n=114,102)96.5 (91.3 to 99.0)98.0 (93.1 to 99.8)
Hib (PRP) ≥ 1.0 μg/mL (n=114,102)85.1 (77.2 to 91.1)89.2 (81.5 to 94.5)
Pertussis PT ≥ 5 EU/mL (n=119,112)100.0 (96.9 to 100.0)100.0 (96.8 to 100.0)
Pertussis PT ≥ 17 EU/mL (n=119,112)96.6 (91.6 to 99.1)95.5 (89.9 to 98.5)
Pertussis FHA ≥ 5 EU/mL (n=119,113)100.0 (96.9 to 100.0)100.0 (96.8 to 100.0)
Pertussis FHA ≥ 7.82 EU/mL (n=119,113)100.0 (96.9 to 100.0)100.0 (96.8 to 100.0)
Pertussis FHA ≥ 20 EU/mL (n=119,113)94.1 (88.3 to 97.6)95.6 (90.0 to 98.5)
Pertussis PRN ≥ 5 EU/mL (n=119,113)100.0 (96.9 to 100.0)100.0 (96.8 to 100.0)
Pertussis PRN ≥ 15 EU/mL (n=119,113)92.4 (86.1 to 96.5)95.6 (90.0 to 98.5)
Pertussis FIM ≥ 2.2 EU/mL (n=119,113)100.0 (96.9 to 100.0)97.3 (92.4 to 99.4)
Pertussis FIM ≥ 5 EU/mL (n=119,113)97.5 (92.8 to 99.5)96.5 (91.2 to 99.0)
Statistical analysis
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -3.8 to 3.9
  • 13vPnC vs 7vPnC · Difference: -1.5 · 95% CI -7.1 to 3.7
  • 13vPnC vs 7vPnC · Difference: -4.1 · 95% CI -13.4 to 5.1
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -3.2 to 3.3
  • 13vPnC vs 7vPnC · Difference: 1.1 · 95% CI -4.5 to 7.1
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -3.2 to 3.2
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -3.2 to 3.2
  • 13vPnC vs 7vPnC · Difference: -1.5 · 95% CI -7.9 to 4.8
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -3.2 to 3.2
  • 13vPnC vs 7vPnC · Difference: -3.1 · 95% CI -10.0 to 3.4
  • 13vPnC vs 7vPnC · Difference: 2.7 · 95% CI -0.5 to 7.6
  • 13vPnC vs 7vPnC · Difference: 1.0 · 95% CI -4.1 to 6.5
SecondaryPercentage of Participants Achieving an SBA Titer ≥1:8 for Meningococcal C in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose.
Time frame:
one month after the toddler dose (13 months of age)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving an SBA Titer ≥1:8 for Meningococcal C in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose.
Percentage of Participants13vPnC Before Toddler Dose7vPnC Before Toddler Dose13vPnC After Toddler Dose7vPnC After Toddler Dose
Percentage of Participants Achieving an SBA Titer ≥1:8 for Meningococcal C in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose.44.1 (34.3 to 54.3)49.5 (38.9 to 60.0)91.7 (84.9 to 96.2)91.8 (84.5 to 96.4)
Statistical analysis
  • 13vPnC Before Toddler Dose vs 7vPnC Before Toddler Dose · Difference: -5.3 · 95% CI -19.7 to 8.8
  • 13vPnC After Toddler Dose vs 7vPnC After Toddler Dose · Difference: -0.1 · 95% CI -8.0 to 8.1
SecondaryPercentage of Participants Achieving a Predefined Antibody Level for Haemophilus Influenzae Type b in the 13vPnC Group Relative to the 7vPnC Group After the Toddler Dose.
Time frame:
one month after toddler dose (13 months of age)
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving a Predefined Antibody Level for Haemophilus Influenzae Type b in the 13vPnC Group Relative to the 7vPnC Group After the Toddler Dose.
Percentage of Participants13vPnC7vPnC
Hib (PRP) ≥0.15 μg/mL100.0 (96.5 to 100.0)100.0 (96.2 to 100.0)
Hib (PRP)≥1.0 μg/mL99.0 (94.8 to 100.0)100.0 (96.2 to 100.0)
Statistical analysis
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -3.5 to 3.8
  • 13vPnC vs 7vPnC · Difference: -1.0 · 95% CI -5.3 to 2.8
PrimaryGeometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series
Time frame:
one month after infant series dose 2 (5 months of age)
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series
titer13vPnC7vPnC
Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series306.20 (251.21 to 373.22)345.42 (287.91 to 414.41)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.89 · 95% CI 0.68 to 1.16
PrimaryGeometric Mean Antibody Concentration of Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series
Time frame:
one month after infant series dose 2 (5 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series
μg/mL13vPnC7vPnC
Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series3.40 (2.65 to 4.37)4.44 (3.50 to 5.63)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.77 · 95% CI 0.54 to 1.08
PrimaryGeometric Mean Antibody Concentration of Pertusis Filamentous Haemagglutinin (FHA), Pertussis Toxoid (PT), Pertactin (PRN), and Fimbrial Agglutinogens (FIM) as Measured by ELISA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series
Time frame:
one month after infant series dose 2 (5 months of age)
Reported as:
Geometric mean · EU/mL
Geometric Mean Antibody Concentration of Pertusis Filamentous Haemagglutinin (FHA), Pertussis Toxoid (PT), Pertactin (PRN), and Fimbrial Agglutinogens (FIM) as Measured by ELISA in 13vPnC Group Relative to 7vPnC Group After the 2-dose Infant Series
EU/mL13vPnC7vPnC
Pertussis FHA (n=119,113)54.74 (48.25 to 373.22)55.99 (49.55 to 414.41)
Pertussis PT (n=119,112)66.26 (59.20 to 74.16)67.05 (58.75 to 76.52)
Pertussis PRN (n=119,113)61.33 (51.78 to 72.65)61.07 (52.31 to 71.30)
Pertussis FIM (n=119,113)21.72 (18.89 to 24.98)21.77 (18.54 to 25.56)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.98 · 95% CI 0.82 to 1.16
  • 13vPnC vs 7vPnC · Ratio: 0.99 · 95% CI 0.83 to 1.17
  • 13vPnC vs 7vPnC · Ratio: 1.00 · 95% CI 0.80 to 1.26
  • 13vPnC vs 7vPnC · Ratio: 1.00 · 95% CI 0.81 to 1.23
SecondaryGeometric Mean Antibody Concentration for Haemophilus Influenzae Type b PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose.
Time frame:
one month after toddler dose (13 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration for Haemophilus Influenzae Type b PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose.
μg/mL13vPnC7vPnC
Geometric Mean Antibody Concentration for Haemophilus Influenzae Type b PRP in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose.22.22 (17.66 to 27.96)19.75 (16.05 to 24.30)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 1.13 · 95% CI 0.83 to 1.53
PrimaryPercentage of Participants in the 13vPnC Group Achieving a Serotype-specific IgG Antibody Concentration ≥0.35 µg/mL Measured 1 Month After the 2-dose Infant Series, Before and After the Toddler Dose

Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
one month after infant series dose 2 (5 months of age), before and after toddler dose (12 months of age)
Reported as:
Number · Percentage of Participants
Percentage of Participants in the 13vPnC Group Achieving a Serotype-specific IgG Antibody Concentration ≥0.35 µg/mL Measured 1 Month After the 2-dose Infant Series, Before and After the Toddler Dose
Percentage of Participants13vPnC After Infant Series Dose 213vPnC Before Toddler Dose13vPnC After Toddler Dose
Common Serotypes - Serotype 4 (n=107,89,102)95.3 (89.4 to 98.5)24.7 (16.2 to 35.0)99.0 (94.7 to 100.0)
Common Serotypes - Serotype 6B (n=107,86,102)40.2 (30.8 to 50.1)74.4 (63.9 to 83.2)98.0 (93.1 to 99.8)
Common Serotypes - Serotype 9V (n=104,91,101)85.6 (77.3 to 91.7)44.0 (33.6 to 54.8)98.0 (93.0 to 99.8)
Common Serotypes - Serotype 14 (n=107,88,101)92.5 (85.8 to 96.7)92.0 (84.3 to 96.7)100.0 (96.4 to 100.0)
Common Serotypes - Serotype 18C (n=111,91,105)92.8 (86.3 to 96.8)13.2 (7.0 to 21.9)97.1 (91.9 to 99.4)
Common Serotypes - Serotype 19F (n=109,91,104)93.6 (87.2 to 97.4)67.0 (56.4 to 76.5)98.1 (93.2 to 99.8)
Common Serotypes - Serotype 23F (n=111,89,104)66.7 (57.1 to 75.3)37.1 (27.1 to 48.0)98.1 (93.2 to 99.8)
Additional Serotypes - Serotype 1 (n=107,88,101)97.2 (92.0 to 99.4)50.0 (39.1 to 60.9)100.0 (96.4 to 100.0)
Additional Serotypes - Serotype 3 (n=107,87,102)86.0 (77.9 to 91.9)12.6 (6.5 to 21.5)88.2 (80.4 to 93.8)
Additional Serotypes - Serotype 5 (n=103,88,101)89.3 (81.7 to 94.5)78.4 (68.4 to 86.5)100.0 (96.4 to 100.0)
Additional Serotypes - Serotype 6A (n=106,86,99)79.2 (70.3 to 86.5)79.1 (69.0 to 87.1)98.0 (92.9 to 99.8)
Additional Serotypes - Serotype 7F (n=107,91,100)94.4 (88.2 to 97.9)71.4 (61.0 to 80.4)100.0 (96.4 to 100.0)
Additional Serotypes - Serotype 19A (n=110,91,103)92.7 (86.2 to 96.8)86.8 (78.1 to 93.0)100.0 (96.5 to 100.0)
PrimaryGeometric Mean Antibody Concentration in 13vPnC Group After the 2-dose Infant Series, Before and After the Toddler Dose.

Antibody concentration/geometric mean concentration (GMC) as measured by ELISA for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented with corresponding 2-sided 95% CI.

Time frame:
one month after infant series dose 2 (5 months of age) and before and after toddler dose (12 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration in 13vPnC Group After the 2-dose Infant Series, Before and After the Toddler Dose.
μg/mL13vPnC After Infant Series Dose 213vPnC Before Toddler Dose13vPnC After Toddler Dose
Common Serotypes - Serotype 4 (n=107,87,87)1.37 (1.16 to 1.62)0.21 (0.17 to 0.24)3.52 (2.91 to 4.26)
Common Serotypes - Serotype 6B (n=107,85,85)0.26 (0.21 to 0.33)0.77 (0.60 to 0.99)7.67 (5.88 to 10.01)
Common Serotypes - Serotype 9V (n=104,88,88)0.87 (0.72 to 1.05)0.29 (0.24 to 0.36)2.46 (2.03 to 2.99)
Common Serotypes - Serotype 14 (n=107,87,87)1.83 (1.47 to 2.27)1.34 (1.09 to 1.66)11.32 (9.27 to 13.83)
Common Serotypes - Serotype 18C (n=111,91,91)1.37 (1.14 to 1.64)0.20 (0.17 to 0.23)2.14 (1.82 to 2.53)
Common Serotypes - Serotype 19F (n=109,90,90)2.38 (1.88 to 3.01)0.60 (0.46 to 0.79)7.25 (5.65 to 9.31)
Common Serotypes - Serotype 23F (n=111,88,88)0.53 (0.42 to 0.67)0.24 (0.19 to 0.32)3.13 (2.59 to 3.78)
Additional Serotypes - Serotype 1 (n=107,85,85)1.69 (1.41 to 2.04)0.39 (0.33 to 0.46)5.60 (4.60 to 6.82)
Additional Serotypes - Serotype 3 (n=107,85,85)0.63 (0.56 to 0.71)0.14 (0.10 to 0.18)0.98 (0.78 to 1.22)
Additional Serotypes - Serotype 5 (n=103,86,86)0.95 (0.79 to 1.14)0.59 (0.49 to 0.72)3.68 (3.04 to 4.45)
Additional Serotypes - Serotype 6A (n=106,83,83)0.86 (0.68 to 1.07)0.81 (0.64 to 1.03)6.31 (5.06 to 7.87)
Additional Serotypes - Serotype 7F (n=107,87,87)2.14 (1.75 to 2.62)0.56 (0.48 to 0.66)4.06 (3.42 to 4.83)
Additional Serotypes - Serotype 19A (n=110,89,89)1.90 (1.54 to 2.34)1.01 (0.77 to 1.32)11.33 (9.29 to 13.83)
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Local Reactions

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting Pre-Specified Local Reactions
Percentage of Participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Toddler Dose7vPnC Toddler Dose
Tenderness-Any (n=123,127,114,96,87,71)44.743.342.140.644.850.7
Tenderness-Significant (n=116,122,97,89,77,58)1.76.64.14.53.93.4
Swelling-Any (n=121,126,106,93,83,68)24.829.430.234.430.139.7
Swelling-Mild (n=120,125,105,93,82,66)21.727.228.629.028.034.8
Swelling-Moderate (n=118,121,98,88,77,60)6.86.68.26.83.911.7
Swelling-Severe (n=115,119,96,88,76,57)0.00.01.00.00.00.0
Redness-Any (n=122,126,107,99,85,73)22.139.739.340.438.853.4
Redness-Mild (n=122,126,106,99,83,71)21.339.737.737.433.749.3
Redness-Moderate (n=116,119,98,88,78,61)1.70.04.13.412.816.4
Redness-Severe (n=115,119,97,88,76,57)0.00.02.10.00.00.0
Other pre-specifiedPercentage of Participants Reporting Pre-Specified Systemic Events

Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds) to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary; percentage of participants with each event was evaluated.

Time frame:
During the 4-day period after each dose
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting Pre-Specified Systemic Events
Percentage of Participants13vPnC Dose 17vPnC Dose 113vPnC Dose 27vPnC Dose 213vPnC Toddler Dose7vPnC Toddler Dose
Fever ≥38°C but ≤39°C (n=116,119,96,88,78,61)6.03.43.14.57.716.4
Fever >39°C but ≤40°C (n=115,119,95,88,76,58)0.90.00.00.00.05.2
Fever >40°C (n=115,119,96,88,76,57)0.00.02.10.00.00.0
Decreased appetite (n=120,129,104,98,92,68)39.234.135.637.839.144.1
Irritability (n=128,135,117,119,97,80)76.674.171.880.774.276.3
Increased sleep (n=129,129,114,109,88,71)69.866.751.856.938.640.8
Decreased sleep (n=119,124,98,100,81,67)32.833.935.738.032.144.8
Meds to treat symptoms (n=123,128,108,110,85,72)43.940.650.954.549.458.3
Meds to prevent symptoms (n=122,124,117,103,92,77)49.240.348.750.552.267.5
SecondaryGeometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Time frame:
one month after toddler dose (13 months of age)
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
titer13vPnC7vPnC
Geometric Mean Titer (GMT) of Meningococcal C Antigen as Measured by SBA in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose656.11 (445.46 to 966.38)771.67 (509.98 to 1167.64)
Statistical analysis
  • 13vPnC vs 7vPnC · Ration: 0.85 · 95% CI 0.48 to 1.49

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Infant Series—1/139 (0.7%)111/138 (80.4%)
7vPnC Infant Series—3/139 (2.2%)105/139 (75.5%)
13vPnC Post-Infant Series—5/139 (3.6%)9/138 (6.5%)
7vPnC Post-Infant Series—2/139 (1.4%)8/139 (5.8%)
13vPnC Toddler Series—1/131 (0.8%)72/130 (55.4%)
7vPnC Toddler Series—2/122 (1.6%)61/122 (50%)
13vPnC 6-Month Follow-up—2/138 (1.4%)1/138 (0.7%)
7vPnC 6-Month Follow-up—0/139 (0%)1/139 (0.7%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC Toddler Series7vPnC Toddler Series13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
FallInjury, poisoning and procedural complications0/1390/1390/1390/1390/1311/1220/1380/139
PneumoniaInfections and infestations0/1390/1390/1390/1390/1311/1220/1380/139
BronchiolitisInfections and infestations1/1390/1391/1390/1391/1310/1220/1380/139
Febrile convulsionNervous system disorders0/1390/1390/1390/1390/1310/1221/1380/139
VomitingGastrointestinal disorders0/1390/1390/1390/1390/1310/1221/1380/139
Breath holdingPsychiatric disorders0/1391/1390/1390/1390/1310/1220/1380/139
CellulitisInfections and infestations0/1391/1390/1390/1390/1310/1220/1380/139
GastroenteritisInfections and infestations0/1390/1391/1390/1390/1310/1220/1380/139
Gastrooesophaegeal refluxGastrointestinal disorders0/1391/1390/1390/1390/1310/1220/1380/139
Head injuryInjury, poisoning and procedural complications0/1390/1391/1390/1390/1310/1220/1380/139
Most frequent other events
Showing 10 of 145
Most frequent other events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Post-Infant Series7vPnC Post-Infant Series13vPnC Toddler Series7vPnC Toddler Series13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
IrritabilityGeneral disorders84/11796/119——————
IrritabilityGeneral disorders98/128100/135——72/9761/80——
Increased sleepGeneral disorders90/12986/129——34/8829/71——
Increased sleepGeneral disorders59/11462/109——————
Erythema (Any)Skin and subcutaneous tissue disorders27/12250/126——33/8539/73——
Tenderness (Any)Skin and subcutaneous tissue disorders55/12355/127——39/8736/71——
Erythema (Mild)Skin and subcutaneous tissue disorders26/12250/126——28/8335/71——
Decreased sleepGeneral disorders39/11942/124——26/8130/67——
Decreased appetiteGeneral disorders47/12044/129——36/9230/68——
Tenderness (Any)Skin and subcutaneous tissue disorders48/11439/96——————

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC7vPnCTotal
Mean2.1 ± 0.32.1 ± 0.22.1 ± 0.3
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC7vPnCTotal
Female5557112
Male6561126
08

Study locations

11 sites
  • Atherstone, CV9 1EU, United Kingdom
  • Bangor, BT19 1NB, United Kingdom
  • Bristol, BS2 8AE, United Kingdom
  • Co Antrim, BT41 3AE, United Kingdom
  • Coventry, CV6 4DD, United Kingdom
  • Ely, CB7 4HF, United Kingdom
  • London, SW17 ORE, United Kingdom
  • Oxford, OX3 9DU, United Kingdom
  • Plymouth, PL5 3JB, United Kingdom
  • Southampton, SO16 6YD, United Kingdom
  • Weston-Super-Mare, BS22 6AJ, United Kingdom
09

References and documents

Publications

  • Rodgers GL, Esposito S, Principi N, Gutierrez-Brito M, Diez-Domingo J, Pollard AJ, Snape MD, Martinon-Torres F, Gruber WC, Patterson S, Thompson A, Gurtman A, Paradiso P, Scott DA. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine. 2013 Oct 1;31(42):4765-74. doi: 10.1016/j.vaccine.2013.08.009. Epub 2013 Aug 16. PubMed 23965217 ↗
  • Snape MD, Klinger CL, Daniels ED, John TM, Layton H, Rollinson L, Pestridge S, Dymond S, Galiza E, Tansey S, Scott DA, Baker SA, Jones TR, Yu LM, Gruber WC, Emini EA, Faust SN, Finn A, Heath PT, Pollard AJ. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010 Dec;29(12):e80-90. doi: 10.1097/inf.0b013e3181faa6be. PubMed 21155091 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 3 years 10 months after primary completion. A results delay was requested in Feb 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2006
First posted
Oct 4, 2006
Start
Oct 2006
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results delay requested
Feb 26, 2009
Results first posted
Aug 15, 2012
Last update
Jan 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00384059
Responsible party
Sponsor
First posted
Oct 4, 2006
Start date
Oct 2006
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Aug 15, 2012
Last update
Jan 24, 2013

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For UK/Great Britian, ukmedinfo@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion